Addressing the second meeting of the committee on effective governance and oversight of human genome editing, Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General, said, “Since our last meeting, some scientists have announced their wish to edit the genome of embryos and bring them to term.
14906
这说明我们的工作极为重要和紧迫。
This illustrates how important our work is, and how urgent.
14907
新的基因组编辑技术为那些患有我们曾经认为无法治愈疾病的人带来了巨大的希望和美好前景。
New genome editing technologies hold great promise and hope for those who suffer from diseases we once thought untreatable.
14908
但这些技术的一些用途也在伦理、社会、监管和技术方面带来了独特的、前所未有的挑战。”
But some uses of these technologies also pose unique and unprecedented challenges – ethical, social, regulatory and technical.”
Dr Tedros emphasized that countries should not allow any further work on human germline genome editing in human clinical applications until the technical and ethical implications have been properly considered.
14910
世卫组织接受了委员会的建议，宣布计划通过世卫组织的国际临床试验注册平台开展第一阶段登记工作。
Accepting the recommendation of the Committee, WHO announced plans for an initial phase of the registry using the International Clinical Trials Registry Platform (ICTRP), a WHO entity.